Prognostic Value of Blasts in Peripheral Blood in Myelofibrosis in the Ruxolitinib Era

BACKGROUND: Peripheral blasts (PB) ≥1% have long been considered an unfavorable feature for patients with primary myelofibrosis (PMF). Whether further quantification of PB blasts and their correlation with bone marrow (BM) blasts has incremental value with regards to patient prognostication is uncle...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer
Главные авторы: Masarova, Lucia, Bose, Prithviraj, Pemmaraju, Naveen, Daver, Naval G., Zhou, Lingsha, Pierce, Sherry, Sasaki, Koji, Kantarjian, Hagop, Estrov, Zeev, Verstovsek, Srdan
Формат: Artigo
Язык:Inglês
Опубликовано: 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7875207/
https://ncbi.nlm.nih.gov/pubmed/32697338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33094
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы